OakChart

Bioline Rx Ltd ADR

BLRXHealthcare·Biotechnology·Israel·Nano·NASD·Nov 11 • 3:43 PM ET

1.49-0.03 (-1.97%)
2026-11-12 03:32 CET
Market cap
7.42 USD m
Revenue, TTM
1.40 USD m
Net income, TTM
-8.03 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-1.82
P/E
-
Compare

Price

BLRX against its 20, 50 and 200-day averages
2050200earnings
2.003.004.00741K1.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BLRXclose 1.4920-day 1.9250-day 2.22200-day 2.691.4952w high

62.3% under the 52-week high of 3.95 on 29 May 2026. 52-week low 1.45 on 10 Nov 2026. Last 15 sessions, 49.4% high to low

Volume 0.37× normal · the line is the 50-bar volume average

Profile

BLRX
52-week range, 2% of the way up
1.453.95

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

Employees24
IPOJul 25, 2011
Beta1.65
ATR, 14d0.15
Rel volume0.37
Short float2.76%
Insider own0.56%
Inst own1.35%

Snapshot

6 groups

Valuation

Index-
Market Cap7.42M
Enterprise Value5.13M
Income-8.03M
Sales1.40M
Book/sh3.15
Cash/sh2.63
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees24
IPOJul 25, 2011

Ratios

P/E-
Forward P/E-
PEG-
P/S5.30
P/B0.47
P/C0.57
P/FCF-
EV/EBITDA-
EV/Sales3.66
Quick Ratio1.04
Current Ratio1.20
Debt/Eq0.58
LT Debt/Eq0.23
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.82
EPS next Y-1.26
EPS next Q-0.39
EPS this Y-
EPS next Y19.75%
EPS next 5Y-
EPS past 3/5Y75.30% 66.78%
Sales past 3/5Y- -
EPS Y/Y TTM55.29%
Sales Y/Y TTM-91.94%
EPS Q/Q31.62%
Sales Q/Q-3.70%
EarningsAug 31 BMO
EPS/Sales Surpr.- -41.20%

Ownership

Insider Own0.56%
Insider Trans0.00%
Inst Own1.35%
Inst Trans28.19%
ROA-20.94%
ROE-47.48%
ROIC-47.39%
Gross Margin55.01%
Oper. Margin-875.98%
Profit Margin-574.29%
SMA20-22.23%
SMA50-33.00%
SMA200-44.62%
Trades-

Technical

Shs Outstand4.98M
Shs Float4.95M
Short Float2.76%
Short Ratio7.87
Short Interest0.14M
52W High3.95 -62.28%
52W Low1.45 2.76%
Volatility10.80% 7.94%
ATR (14)0.15
RSI (14)17.47
Beta1.65
Rel Volume0.37
Avg Volume17.35K
Volume6,368

Performance

Perf Week-19.89%
Perf Month-31.34%
Perf Quarter-45.19%
Perf Half Y-52.40%
Perf YTD-46.21%
Perf Year-55.39%
Perf 3Y-97.40%
Perf 5Y-98.67%
Perf 10Y-99.78%
Recom1.00
Target Price22.00
Prev Close1.52
Price1.49
Change %-1.97%

Analyst ratings

latest 6 of 6
DateActionAnalystRating changeTargetImplied
May 18, 2017UpgradeMMaxim GroupHold → Buy$1 → $3+101.3%
Feb 13, 2017InitiatedRRodman & RenshawBuy$3+101.3%
Aug 12, 2016DowngradeMMaxim GroupBuy → Hold$4 → $1-32.9%
Aug 17, 2015ReiteratedMMaxim GroupBuy$8 → $4+168.5%
Jul 27, 2015ReiteratedRROTH CapitalBuy$10.50 → $7+369.8%
Jun 22, 2015InitiatedJJMP SecuritiesMkt Outperform$5+235.6%

Peers

Mkt cap
TickerCompanyMkt cap
CNSPCns Pharmaceuticals Inc5.29M
KZIAKazia Therapeutics Limited ADR84.92M
XFORX4 Pharmaceuticals Inc329.83M
NTHINeOnc Technologies Holdings Inc130.41M
BDRXBiodexa Pharmaceuticals Plc ADR1.25M
MBRXMoleculin Biotech Inc8.50M
TOVXTheriva Biologics Inc7.39M
ELTXElicio Therapeutics Inc46.14M
CANFCan-Fite Biopharma Ltd ADR4.71M
PPBTPurple Biotech Ltd ADR2.41M

News

latest 14 of 200
  • BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026 (PR Newswire)
  • BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day (PR Newswire)
  • BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) (PR Newswire)
  • BioLine Rx Ltd (BLRX) (Q2 2026) Earnings Call Highlights: Advancing GLIX1 Pipeline and ... (GuruFocus.com) +7.69%
  • BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire)
  • BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement (PR Newswire) -5.80%
  • BioLineRx to Report Second Quarter 2026 Results on August 31, 2026 (PR Newswire) -5.00%
  • BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026 (PR Newswire)
  • BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model (PR Newswire)
  • BioLine Rx Ltd (BLRX) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com)
  • BioLineRx Shares Advance After First Patient Enrolled in GLIX1 Cancer Study (BLRX) (InvestorsHub) +6.65%
  • BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire)
  • BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting (PR Newswire) +6.99%
  • BioLineRx to Report First Quarter 2026 Results on May 27, 2026 (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-310.0000.0000.0000.290.501
2026Q12026-05-270.000-1.040-0.5800.480.341
2025Q42026-03-23-0.270-0.385-0.3200.190.512
2025Q32025-11-240.000-0.670-0.2230.430.991
2025Q22025-08-140.000-0.353-1.0170.300.663
2025Q12025-05-270.000-0.9501.3790.261.482
2024Q42025-03-31-1.270-0.807-1.51211.757.723
2024Q32024-11-250.000-1.742-2.9194.945.293
2024Q22024-08-150.000-3.0000.2395.393.932
2024Q12024-05-280.000-11.600-0.3886.900.341
2023Q42024-03-26-7.600-8.800-7.7514.800.151
2023Q32023-11-20-11.940-8.400-10.3130.000.001
2023Q22023-08-30-11.940-6.800-11.9120.000.001
2023Q12023-05-24-5.972-5.600-7.8340.000.002
2022Q42023-03-22-3.600-5.400-3.7160.000.002
2022Q32022-11-15-5.972-6.600-5.5000.000.002

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-101.49-92.268-104.620.000.00
2020FY-71.640-47.200-71.7380.000.00
2021FY-23.880-26.600-24.5030.000.00
2022FY-17.912-21.600-19.2680.000.00
2023FY-36.000-39.396-37.6554.800.15
2024FY-6.000-2.951-4.64228.9424.91
2025FY0.000-0.3400.0001.181.46
2026FY--1.570--1.62
2027FY--1.260--2.22
2028FY-0.000--7.84
2029FY--0.600--7.40
2030FY--0.320--17.26

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-312000.360.340.38
2026Q3S2026-07-301000.380.380.38
2026Q3S2026-06-092000.380.380.38
2026Q3S2026-05-272010.380.380.38
2026Q3S2026-03-261010.380.380.38
2026Q3S2026-02-071000.690.690.69
2026Q3S2025-11-241010.690.690.69
2026Q3S2025-11-111001.781.781.78
2026Q3S2025-11-101001.781.781.78
2026Q3S2025-11-091001.781.781.78
2026Q3S2025-11-081001.781.781.78
2026Q3S2025-11-071001.781.781.78
2026Q3S2025-11-061001.781.781.78
2026Q3S2025-11-051001.781.781.78

Estimate history

EPS, annual-163.148-126.452-104.617-71.738-24.503-19.268-37.655-4.642-0.29-1.8192
Period201720182019202020212022202320242025TTM
EPS, quarterly0.239-2.919-1.5121.379-1.017-0.223-0.32-0.58-0.696
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000004.78829.0771.1891.4
Period201720182019202020212022202320242025TTM
Sales, quarterly5.3724.95811.8430.2540.3110.4290.1950.4760.299
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.1750.1920.2850.5821.1921.5381.8112.2284.3514.368
Period201720182019202020212022202320242025MRQ
Shares, quarterly1.99822.2283.7214.2634.3514.3514.3514.368
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue1.401.1929.084.790.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.630.7610.084.610.650.700.940.940.45
Gross Profit0.770.4319.000.17-0.65-0.70-0.94-0.94-0.45
Selling, General and Administrative Excl. Other13.0210.8038.4943.0528.3924.0922.1527.2625.07
Research and Development9.687.668.7611.9116.9518.8217.4322.6519.32
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-12.25-10.37-19.49-42.88-29.04-24.79-23.09-28.20-25.52
Interest Expense1.051.299.162.161.801.011.501.860.47
Unusual Expense0.00-8.67-18.0417.71-6.401.945.18-4.65-1.74
Net Income Before Taxes-10.23-2.04-9.26-60.46-24.85-27.07-30.23-25.53-22.89
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-10.23-2.04-9.26-60.46-24.85-27.07-30.23-25.53-22.89
Net Income From Continuing Operations-8.03-1.18-9.26-60.46-24.85-27.07-30.23-25.53-22.89
Net Income-8.03-1.18-9.26-60.46-24.85-27.07-30.23-25.53-22.89
EPS (Recurring)-1.81-1.76-10.96-29.93-22.74-23.28-63.14-117.96-133.17
EPS (Basic, Before Extraordinaries)-1.82-0.29-4.64-37.65-19.27-24.50-71.74-104.62-126.45
EPS (Diluted)-1.82-0.29-4.64-37.65-19.27-24.50-71.74-104.62-126.45
EBITDA-11.90-9.84-15.38-41.50-28.39-24.09-22.15-27.26-25.07
Non-Operating Income (Expense)3.080.951.352.30-0.410.67-0.46-0.121.37
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.350.401.041.542.081.561.281.361.91
Price To Sales Ratio9.919.570.5921.06-----
Gross Margin55.0136.1965.333.63-----
Operating Margin-875.98-871.78-67.03-895.65-----
Net Margin-574.29-99.58-31.86-1,262.79-----
Shares Outstanding4.374.352.231.811.541.190.580.290.19
Market Capitalization7.427.4219.07101.5236.3097.2658.6625.6950.26

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.300.480.200.430.310.2511.844.96
Cost of Goods Sold Incl. D&A0.140.180.100.200.250.206.251.24
Gross Profit0.160.290.090.230.060.065.593.72
Selling, General and Administrative Excl. Other3.793.293.502.442.412.439.039.12
Research and Development2.992.522.441.732.381.611.882.57
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-3.63-3.00-3.41-2.22-2.35-2.38-3.44-5.40
Interest Expense0.210.250.280.310.280.424.521.63
Unusual Expense0.000.000.000.000.000.001.020.00
Net Income Before Taxes-4.41-2.58-2.25-0.98-4.025.10-3.21-5.84
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-4.41-2.58-2.25-0.98-4.025.10-3.21-5.84
Net Income From Continuing Operations-3.08-2.58-1.39-0.98-4.025.10-3.21-5.84
Net Income-3.08-2.58-1.39-0.98-4.025.10-3.21-5.84
EPS (Recurring)-0.69-0.58-0.32-0.23-1.021.38-1.18-2.92
EPS (Basic, Before Extraordinaries)-0.70-0.58-0.32-0.22-1.021.38-1.51-2.92
EPS (Diluted)-0.70-0.58-0.32-0.22-1.021.38-1.51-2.92
EBITDA-3.56-2.91-3.34-2.10-2.17-2.21-1.55-4.56
Non-Operating Income (Expense)-0.570.661.441.54-1.397.905.761.19
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.080.060.130.080.040.150.080.26
Price To Sales Ratio9.917.2310.141.281.040.490.621.94
Gross Margin53.4061.6446.9152.4618.4221.9647.2175.02
Operating Margin-1,215.31-629.77-1,745.36-516.86-757.57-937.65-29.07-108.98
Net Margin-1,029.25-542.56-713.92-228.81-1,296.052,010.59-27.13-117.78
Shares Outstanding4.374.354.354.354.263.722.232.00
Market Capitalization7.4210.0112.0516.1119.4811.0119.0742.88

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments20.8819.5642.9951.0857.1422.5927.4930.1549.48
Short Term Receivables0.463.860.710.720.140.140.611.340.59
Inventories2.153.141.950.000.000.000.000.000.00
Other Current Assets0.200.531.530.200.130.150.110.490.31
Total Current Assets23.6827.1047.1852.0057.4022.8828.2131.9850.38
Net Property, Plant & Equipment0.861.351.892.502.282.703.472.232.51
Total Investments and Advances0.000.000.000.000.000.000.000.001.00
Intangible Assets16.3710.4514.8521.8921.7021.7121.8921.977.02
Other Assets0.000.000.000.000.000.000.000.060.06
Total Assets40.9038.9163.9376.3881.3947.2953.5756.2360.97
Short Term Debt Incl. Current Port. of LT Debt4.715.003.671.972.933.282.890.890.09
Accounts Payable3.495.5810.876.975.575.927.794.495.52
Other Current Liabilities3.924.8216.311.741.231.441.281.361.11
Total Current Liabilities12.1215.4130.8510.689.7210.6411.976.756.72
Long Term Debt5.4410.047.9210.361.734.407.567.840.16
Provision for Risks Charges0.000.000.000.000.000.000.000.00-
Other Liabilities0.000.0011.934.511.8610.220.660.321.21
Total Liabilities17.5625.4450.7025.5413.3025.2620.1914.918.08
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity18.2013.4613.2250.8468.0922.0333.3841.3252.88
Total Shareholders Equity18.2013.4613.2250.8468.0922.0333.3841.3252.88
Accumulated Minority Interest5.150.000.000.000.000.000.000.000.00
Total Equity23.3413.4613.2250.8468.0922.0333.3841.3252.88
Total Liabilities & Stockholders Equity40.9038.9163.9376.3881.3947.2953.5756.2360.97
Book Value Per Share4.186.047.3033.0557.1237.86116.94215.71302.00
Tangible Book Value Per Share0.421.35-0.9018.8238.910.5440.25101.01261.89
Full-Time Employees242838493838424851
Price to Book Ratio0.471.427.730.651.432.660.771.221.92
Return on Assets-2.97-18.02-86.18-31.50-42.08-59.95-46.50-39.06-49.11
Return on Equity-7.48-69.44-188.74-41.80-60.08-109.12-68.35-48.59-55.82
Return on Invested Capital-5.01-39.42-285.97-40.61-38.78-114.38-62.35-46.56-46.24
Quick Ratio1.781.561.474.875.912.152.364.747.49
Current Ratio1.951.761.534.875.912.152.364.747.49

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-10.21-2.04-9.26-60.46-24.85-27.07-30.23-25.53-22.89
Depreciation0.350.534.081.380.650.700.940.940.54
Other Funds (Non Cash)-1.73-7.89-16.9821.37-3.173.327.22-2.49-0.07
Funds from Operations-11.59-9.41-22.16-37.71-27.37-23.05-22.07-27.08-22.41
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.701.27-21.9215.161.23-0.54-1.304.34-1.70
Cash from Operating Activities-10.88-8.14-44.08-22.55-26.14-23.59-23.37-22.74-24.11
Capital Expenditures-0.00-0.03-0.05-0.30-0.31-0.100.00-0.07-10.18
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses-0.010.000.000.000.000.000.000.000.00
Purchase or Sale of Investments12.51-8.5929.571.744.31-38.1516.785.3519.71
Purchase of Investments-19.64-36.93-26.48-47.47-43.83-78.05-33.74-43.69-26.41
Sale Or Maturity of Investments32.1528.3556.0449.2048.1339.9050.5249.0346.12
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities12.48-8.6129.511.443.99-38.2516.785.279.52
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.3914.0016.4617.0014.3161.3621.3720.363.82
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.3914.0016.4617.0014.3161.3621.3720.363.82
Proceedsfrom Stock Options14.0014.0016.4314.0514.3050.440.000.000.00
Issuance or Reduction of Debt, Net-4.53-4.534.81-1.546.27-3.38-3.15-1.11-0.41
Change in Long Term Debt-4.53-4.534.81-1.546.27-3.38-3.15-1.11-0.41
Issuance of Long Term Debt0.000.0019.310.009.090.00-0.000.00
Reduction of Long Term Debt-4.53-4.53-14.50-1.54-2.82-3.38-3.15-1.11-0.41
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.009.65
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities-4.528.9520.7615.0220.3657.7917.9919.2613.05
Exchange Rate Effect0.340.550.02-0.22-0.600.210.210.11-0.17
Net Change in Cash-2.58-7.246.21-6.32-2.39-3.8411.611.90-1.70
Free Cash Flow--8.16-44.13-22.67-26.27-23.69-23.37-22.81-24.29
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments13.0817.3520.8825.2128.1626.37
Short Term Receivables0.731.890.460.700.281.92
Inventories2.172.162.152.182.853.32
Other Current Assets0.380.180.200.430.570.31
Total Current Assets16.3521.5823.6828.5231.8631.92
Net Property, Plant & Equipment0.800.870.860.891.001.16
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets16.3316.3516.3710.3910.4110.43
Other Assets0.000.000.000.000.000.00
Total Assets33.4838.8040.9039.8043.2743.51
Short Term Debt Incl. Current Port. of LT Debt4.764.734.714.784.895.12
Accounts Payable4.294.913.493.543.474.69
Other Current Liabilities4.633.993.925.367.134.21
Total Current Liabilities13.6813.6212.1213.6715.4814.03
Long Term Debt3.184.345.446.607.728.62
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities16.8617.9617.5620.2723.2022.65
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity13.7716.6718.2019.5320.0720.86
Total Shareholders Equity13.7716.6718.2019.5320.0720.86
Accumulated Minority Interest2.854.165.150.000.000.00
Total Equity16.6220.8423.3419.5320.0720.86
Total Liabilities & Stockholders Equity33.4838.8040.9039.8043.2743.51
Book Value Per Share3.153.834.184.494.715.61
Tangible Book Value Per Share-0.590.070.422.102.272.80
Full-Time Employees--24---
Price to Book Ratio0.470.550.620.800.820.70
Return on Assets-20.94-21.82-3.26-6.74-14.79-7.30
Return on Equity-47.48-47.85-8.21-22.24-46.84-20.45
Return on Invested Capital-18.16-12.28-5.90-3.76-14.4817.30
Quick Ratio1.041.431.781.931.872.04
Current Ratio1.201.581.952.092.062.27

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-4.39-2.58-2.25-0.98-3.935.13
Depreciation0.080.090.060.120.180.16
Other Funds (Non Cash)0.76-0.29-1.12-1.071.67-7.37
Funds from Operations-3.55-2.79-3.31-1.94-2.08-2.08
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.290.510.08-0.181.88-0.51
Cash from Operating Activities-3.26-2.27-3.23-2.12-0.20-2.59
Capital Expenditures0.01-0.01-0.030.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.00-0.010.010.00
Purchase or Sale of Investments6.412.70-0.323.72-3.81-8.18
Purchase of Investments-2.55-5.17-7.70-4.22-12.71-12.31
Sale Or Maturity of Investments8.967.877.387.948.904.13
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities6.422.70-0.353.71-3.80-8.18
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.040.000.010.332.9610.70
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.040.000.010.332.9610.70
Proceedsfrom Stock Options0.000.000.0113.99-10.7010.70
Issuance or Reduction of Debt, Net-1.14-1.12-1.15-1.13-1.14-1.12
Change in Long Term Debt-1.14-1.12-1.15-1.13-1.14-1.12
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-1.14-1.12-1.15-1.13-1.14-1.12
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-1.16-1.18-1.25-0.931.699.45
Exchange Rate Effect0.130.010.130.070.43-0.08
Net Change in Cash2.13-0.74-4.700.73-1.87-1.40
Free Cash Flow-3.26-2.28-3.25---2.59

Revenue breakdown

Pharmaceutical Preparations2024: 28.94M 2025: 1.18M
Country of domicile2024: 13.98M 2025: 1.18M
Foreign countries2024: 14.96M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.76%0.1M5.0M16.85K
2026-10-152.77%0.1M5.0M17.17K
2026-09-302.94%0.1M5.0M19.32K
2026-09-153.02%0.1M4.8M20.26K
2026-08-312.82%0.1M4.8M19.65K
2026-08-143.10%0.1M4.3M46.38K
2026-07-313.11%0.1M4.3M48.66K
2026-07-153.36%0.1M4.3M53.24K
2026-06-303.15%0.1M4.3M49.88K
2026-06-153.35%0.1M4.3M49.67K
2026-05-293.84%0.2M4.3M48.31K
2026-05-153.21%0.1M4.3M18.26K
2026-04-303.64%0.2M4.3M17.20K
2026-04-153.57%0.2M4.3M14.71K
2026-03-313.78%0.2M4.3M14.89K
2026-03-133.87%0.2M4.3M16.60K
2026-02-273.91%0.2M4.3M19.02K
2026-02-133.86%0.2M4.3M22.49K
2026-01-304.00%0.2M4.3M23.55K
2026-01-154.08%0.2M4.3M24.71K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.002.300.500.00033.000.000.0000.0000.000
call5.000.000.800.0513.0722960.000.697-0.0580.001
call7.500.005.000.1015.23514.000.000.693-0.0700.001
put2.500.005.000.000.0000.000.000.0000.0000.000
put5.001.106.000.000.0000.000.00-0.296-0.0630.001
put7.503.508.500.000.0000.000.00-0.307-0.0690.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-23SEC
2026-10-02EFFECTEffectiveness filing by commission orderSEC
2026-10-02424B3SEC
2026-09-25F-1Registration statement for certain foreign private issuersSEC
2026-09-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-24SEC
2026-09-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-10SEC
2026-09-09DNotice of sales of securities on Form D (Regulation D)SEC
2026-08-31424B5SEC
2026-08-316-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-31SEC
2026-08-316-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-08-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-08-28SEC
2026-08-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-18SEC
2026-07-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-08SEC
2026-05-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-27SEC
2026-05-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-22SEC
2026-05-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-19SEC
2026-04-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-28SEC
2026-04-103Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-313Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-313Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-313Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-313Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-303Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-303Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-2720-F/A2025-12-31SEC
2026-03-273Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-26SEC
2026-03-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-23SEC
2026-03-2320-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.71%
RENAISSANCE TECHNOLOGIES LLC0.35%
CITADEL ADVISORS LLC0.34%
RHUMBLINE ADVISERS0.05%
WELLS FARGO & COMPANY/MN0.05%
BNP PARIBAS FINANCIAL MARKETS0.01%
Nemes Rush Group LLC0.01%
UBS Group AG0.00%
NewEdge Advisors, LLC0.00%
BFC Planning, Inc.0.00%

Funds

Fund% owned
-

OakChart. BLRX. Cached 15 minutes.

Some panels did not load: insider.